Company Overview - Established in 1994, the company underwent a complete restructuring in 2000 and has focused on gene-engineered drugs since then. Key products include G-CSF and rh-bFGF, which were launched in 1998 and 2000 respectively [2][3]. - The company was listed on the Shenzhen Stock Exchange in 2004, with net profit increasing from approximately 30 million CNY at the time of listing to nearly 1 billion CNY [2][3]. Financial Performance - Cumulative dividends paid by the company have reached 2.12 billion CNY, exceeding the raised capital by over ten times [3][10]. - The company has not engaged in any financing since its initial public offering, relying solely on self-generated funds for development and investments exceeding 1 billion CNY [3]. Research and Development - The company has nearly 80 products in its portfolio, with over 20 projects at various stages of research and development [3]. - Key innovative drugs under development include: - Long-acting recombinant human follicle-stimulating hormone injection - GLP-1-Fc fusion protein (Dulaglutide) - PEGylated G-CSF injection [4][5]. - The company is also developing a unique anti-platelet aggregation drug in collaboration with a U.S. partner, currently in Phase II clinical trials [4][5][6]. Product Launches and Market Potential - The company recently launched a nitroglycerin spray, which is the only formulation of its kind in China, showing significant market potential due to its rapid efficacy in treating angina and myocardial infarction [7][8]. - The company is actively promoting this product through various strategies, including academic conferences and collaborations with pharmaceutical sales channels [8]. Sales and Marketing Strategy - The company is transitioning from hospital-focused sales to online platforms, with a growing presence on e-commerce sites like JD.com [11]. - The sales of coenzyme products, once accounting for over 70% of revenue, are being revitalized due to increased public awareness of cardiovascular health [9][10]. Competitive Landscape - The company has successfully secured bids in national centralized procurement for 25 products across various therapeutic areas, including oncology and cardiovascular diseases [12]. - Notable products include Temozolomide capsules and Apixaban, which have shown rapid sales growth [12]. Investment and Future Outlook - The company holds a 55.69% stake in Beijing New Mile Health Industry Group, which is expected to yield positive returns in the future [13]. - The establishment of a gene-editing platform in collaboration with a U.S. company is anticipated to enhance the company's capabilities in therapeutic antibody development [6].